Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jul;24(7):711-712.
doi: 10.18553/jmcp.2018.24.7.711.

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma

Sikander Ailawadhi  1 , Sumeet Panjabi  2 , Marco Campioni  3 , Istvan Majer  3 , Andrzej Jakubowiak  4
Affiliations
Comment

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma

Sikander Ailawadhi et al. J Manag Care Spec Pharm. 2018 Jul.

Abstract

Ailawadhi reports research support from Pharmacyclics and consulting relationships with Takeda, Amgen, and Celgene. Jakubowiak reports consulting and advisory board relationships with AbbVie, Amgen, BMS, Celgene, Karyopharm, SkylineDX, and Takeda. Panjabi, Campioni, and Majer are employees of and stockholders in Amgen.

PubMed Disclaimer

Conflict of interest statement

Ailawadhi reports research support from Pharmacyclics and consulting relationships with Takeda, Amgen, and Celgene. Jakubowiak reports consulting and advisory board relationships with AbbVie, Amgen, BMS, Celgene, Karyopharm, SkylineDX, and Takeda. Panjabi, Campioni, and Majer are employees of and stockholders in Amgen.

Comment in

Comment on

References

    1. Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2018;24(1):29-38. Available at: https://www.jmcp.org/doi/10.18553/jmcp.2018.24.1.29. - DOI - PMC - PubMed
    1. National Institute for Health and Care Excellence. Panobinostat for treating multiple myeloma for a least 2 previous treatments. Technology Appraisal Guidance 380. January 27, 2016. Available at: www.nice.org.uk/guidance/ta380. Accessed June 6, 2018.
    1. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-66. - PubMed
    1. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327-37. - PubMed
    1. National Institute for Health for Care Excellence. Carfilzomib for previously treated multiple myeloma. June 2017. Available at: https://www.nice.org.uk/guidance/ta457/documents/final-appraisal-determi.... Accessed June 6, 2018.

LinkOut - more resources